Sunday, March 22, 2015 12:26:32 PM
Jez Moulding the President of Sanofi NA on Afrezza
He is also a diabetics expert.
http://blog.sanofi.us/2015/02/25/one-giant-leap-for-mannkind-sanofi/
One Giant Leap for MannKind [& Sanofi]
In October, I arrived in the U.S. from my former post as head of Sanofi’s Japan/Pacific region, which includes Japan, Australia, New Zealand and South Korea. Since that time, I’ve spent a lot of time listening and asking questions, and in the process, I’m beginning to learn more about our teams in America and Canada.
What I’ve learned in that time is that we have a dynamic, talented team in Sanofi US. We have the potential to launch seven new products in the U.S. by 2017. With this opportunity to reach millions of patients with our medicines, I find myself more energized now than at other point in my career.
Earlier this month, our team celebrated an especially significant milestone, launching the first of those seven new products. Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in the U.S. Click here for Full Prescribing Information for Afrezza® including Boxed WARNING.
To me, the launch of Afrezza embodies the type of innovation we strive for – not only bringing a new treatment option to market, but doing so with a treatment that can address challenges people living with diabetes face.
When we announced our global licensing agreement with MannKind Corporation last summer, we knew there was a great deal to be done in a short period of time. This launch would not have been possible without the hard work of our dedicated colleagues and the collaboration of our counterparts at MannKind.
We’re ready for a promising year ahead, and this is an exciting start.
www.Afrezza.com.
Regards,
Jez Moulding
President, North America Pharmaceuticals
He is also a diabetics expert.
http://blog.sanofi.us/2015/02/25/one-giant-leap-for-mannkind-sanofi/
One Giant Leap for MannKind [& Sanofi]
In October, I arrived in the U.S. from my former post as head of Sanofi’s Japan/Pacific region, which includes Japan, Australia, New Zealand and South Korea. Since that time, I’ve spent a lot of time listening and asking questions, and in the process, I’m beginning to learn more about our teams in America and Canada.
What I’ve learned in that time is that we have a dynamic, talented team in Sanofi US. We have the potential to launch seven new products in the U.S. by 2017. With this opportunity to reach millions of patients with our medicines, I find myself more energized now than at other point in my career.
Earlier this month, our team celebrated an especially significant milestone, launching the first of those seven new products. Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in the U.S. Click here for Full Prescribing Information for Afrezza® including Boxed WARNING.
To me, the launch of Afrezza embodies the type of innovation we strive for – not only bringing a new treatment option to market, but doing so with a treatment that can address challenges people living with diabetes face.
When we announced our global licensing agreement with MannKind Corporation last summer, we knew there was a great deal to be done in a short period of time. This launch would not have been possible without the hard work of our dedicated colleagues and the collaboration of our counterparts at MannKind.
We’re ready for a promising year ahead, and this is an exciting start.
www.Afrezza.com.
Regards,
Jez Moulding
President, North America Pharmaceuticals
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
